<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8" />
  <title>PromptGenix – Research Strategy (Approach)</title>
  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <meta name="description" content="Phase I research strategy and approach: automated RNA-Seq and flow cytometry pipelines + PubMed-aware hypothesis generator, validated on public datasets." />

  <style>
    * { box-sizing: border-box; }
    html, body { height: 100%; }

    body {
      margin: 0;
      font-family: -apple-system, BlinkMacSystemFont, "Segoe UI", sans-serif;
      background: #020617;
      color: #e5e7eb;
      line-height: 1.55;
    }

    a { color: inherit; text-decoration: none; }

    .page {
      min-height: 100vh;
      display: flex;
      flex-direction: column;
    }

    header {
      position: sticky;
      top: 0;
      z-index: 20;
      backdrop-filter: blur(14px);
      background: rgba(15, 23, 42, 0.92);
      border-bottom: 1px solid rgba(148, 163, 184, 0.25);
    }

    .nav {
      max-width: 1120px;
      margin: 0 auto;
      padding: 14px 20px;
      display: flex;
      align-items: center;
      justify-content: space-between;
      gap: 20px;
      flex-wrap: wrap;
    }

    .nav-left {
      display: flex;
      align-items: center;
      gap: 12px;
    }

    .logo-dot {
      width: 28px;
      height: 28px;
      border-radius: 999px;
      background: radial-gradient(circle at 0 0,#38bdf8,#8b5cf6);
      box-shadow: 0 0 18px rgba(56,189,248,.7);
      flex: 0 0 auto;
    }

    .brand {
      font-size: 1.05rem;
      font-weight: 700;
      letter-spacing: 0.04em;
      line-height: 1.1;
    }

    .brand-sub {
      font-size: .72rem;
      color: #9ca3af;
      margin-top: 2px;
    }

    .nav-links {
      display: flex;
      gap: 10px;
      font-size: .88rem;
      color: #9ca3af;
      flex-wrap: wrap;
      justify-content: center;
    }

    .nav-links a {
      padding: 6px 10px;
      border-radius: 999px;
      border: 1px solid transparent;
    }

    .nav-links a:hover {
      color: #e5e7eb;
      background: rgba(148, 163, 184, 0.14);
      border-color: rgba(148, 163, 184, 0.18);
    }

    .nav-links a.active {
      color: #e5e7eb;
      background: rgba(148, 163, 184, 0.18);
      border-color: rgba(148, 163, 184, 0.22);
    }

    .nav-cta {
      display: flex;
      gap: 10px;
      align-items: center;
      margin-left: auto;
    }

    .btn {
      border-radius: 999px;
      border: 1px solid rgba(148, 163, 184, 0.55);
      padding: 8px 14px;
      font-size: .85rem;
      cursor: pointer;
      background: transparent;
      color: #e5e7eb;
      display: inline-block;
      white-space: nowrap;
    }

    .btn-primary {
      border: none;
      background: linear-gradient(135deg,#22c55e,#22d3ee,#6366f1);
      color: #020617;
      font-weight: 650;
      box-shadow: 0 0 22px rgba(59,130,246,0.45);
    }

    .btn-primary:hover { filter: brightness(1.05); }
    .btn-outline:hover { background: rgba(148, 163, 184, 0.18); }

    main { flex: 1; }

    .section {
      max-width: 1120px;
      margin: 0 auto;
      padding: 34px 20px;
    }

    .hero {
      padding-top: 30px;
      padding-bottom: 16px;
    }

    .badge-row {
      display: flex;
      flex-wrap: wrap;
      gap: 8px;
      margin-bottom: 14px;
    }

    .badge {
      font-size: .7rem;
      text-transform: uppercase;
      letter-spacing: .12em;
      border-radius: 999px;
      padding: 5px 11px;
      border: 1px solid rgba(251,191,36,0.55);
      color: #fed7aa;
      background: rgba(120,53,15,0.35);
    }

    .badge.info {
      border-color: rgba(56,189,248,0.55);
      color: #bae6fd;
      background: rgba(15,23,42,0.9);
    }

    .title {
      font-size: clamp(1.9rem, 2.2vw + 1.2rem, 2.55rem);
      font-weight: 780;
      letter-spacing: 0.01em;
      color: #f9fafb;
      margin: 10px 0 10px;
      line-height: 1.15;
    }

    .lede {
      font-size: 1.02rem;
      color: #e5e7eb;
      max-width: 58rem;
      margin: 0 0 14px;
    }

    .meta {
      font-size: .84rem;
      color: #9ca3af;
      margin-top: 10px;
    }

    .grid {
      display: grid;
      grid-template-columns: minmax(0,1fr) minmax(0,1fr);
      gap: 18px;
      margin-top: 18px;
      align-items: start;
    }

    .card {
      border-radius: 16px;
      padding: 16px 18px;
      background: rgba(15,23,42,0.92);
      border: 1px solid rgba(55,65,81,0.85);
      box-shadow: 0 18px 35px rgba(15,23,42,0.55);
    }

    .kicker {
      font-size: .78rem;
      text-transform: uppercase;
      letter-spacing: .18em;
      color: #a5b4fc;
      margin-bottom: 6px;
    }

    h2 {
      margin: 0 0 10px;
      font-size: 1.22rem;
      color: #f9fafb;
      letter-spacing: 0.01em;
    }

    p { margin: 0 0 10px; color: #d1d5db; font-size: .94rem; }

    ul {
      padding-left: 1.1rem;
      margin: 8px 0 0;
      color: #d1d5db;
      font-size: .92rem;
    }

    li { margin-bottom: 6px; }

    .callout {
      border-radius: 14px;
      padding: 12px 14px;
      border: 1px dashed rgba(148, 163, 184, 0.5);
      background: rgba(2,6,23,0.35);
      font-size: .9rem;
      color: #e5e7eb;
      margin-top: 10px;
    }
    .callout strong { color: #22c55e; }

    .mini {
      font-size: .82rem;
      color: #9ca3af;
      margin-top: 8px;
    }

    /* Table */
    .table-wrap {
      overflow: auto;
      border-radius: 14px;
      border: 1px solid rgba(55,65,81,0.85);
      background: rgba(2,6,23,0.25);
    }

    table {
      width: 100%;
      border-collapse: collapse;
      min-width: 760px;
    }

    th, td {
      padding: 12px 12px;
      border-bottom: 1px solid rgba(55,65,81,0.7);
      vertical-align: top;
      font-size: .9rem;
      color: #d1d5db;
    }

    th {
      text-align: left;
      font-size: .78rem;
      text-transform: uppercase;
      letter-spacing: .12em;
      color: #c7d2fe;
      background: rgba(15,23,42,0.78);
      position: sticky;
      top: 0;
      z-index: 1;
    }

    tr:last-child td { border-bottom: none; }

    .pill {
      display: inline-block;
      font-size: .72rem;
      padding: 4px 8px;
      border-radius: 999px;
      background: rgba(15,23,42,0.9);
      border: 1px solid rgba(129,140,248,0.45);
      color: #c7d2fe;
      margin: 2px 6px 2px 0;
      white-space: nowrap;
    }

    footer {
      border-top: 1px solid rgba(31,41,55,0.9);
      padding: 16px 20px 22px;
      font-size: .78rem;
      color: #6b7280;
      text-align: center;
      background: #020617;
    }

    @media (max-width: 880px) {
      .grid { grid-template-columns: minmax(0,1fr); }
      .nav-cta { margin-left: 0; width: 100%; justify-content: flex-start; }
      .nav { gap: 12px; }
      table { min-width: 680px; }
    }
  </style>
</head>

<body>
<div class="page">

  <!-- HEADER -->
  <header>
    <div class="nav">
      <div class="nav-left">
        <div class="logo-dot"></div>
        <div>
          <div class="brand">PromptGenix</div>
          <div class="brand-sub">Research Strategy – Approach (Phase I)</div>
        </div>
      </div>

      <nav class="nav-links">
        <a href="sbir.html">SBIR Landing</a>
        <a href="aims.html">Specific Aims</a>
        <a href="approach.html" class="active">Approach</a>
      </nav>

      <div class="nav-cta">
        <a class="btn btn-outline" href="mailto:dohoon.kim1@icloud.com?subject=PromptGenix%20SBIR%20Approach%20Question">Email</a>
        <a class="btn btn-primary" href="#validation">Jump to Validation Plan</a>
      </div>
    </div>
  </header>

  <main>

    <!-- HERO -->
    <section class="section hero">
      <div class="badge-row">
        <span class="badge">Phase I</span>
        <span class="badge info">Public-data validation</span>
        <span class="badge info">PubMed-aware hypothesis generator</span>
      </div>

      <h1 class="title">Research Strategy – Approach</h1>

      <p class="lede">
        Phase I integrates hardened automated pipelines for <strong>RNA-Seq</strong> and <strong>flow cytometry</strong>
        with a literature-aware LLM layer that produces <strong>traceable interpretations</strong> and a
        <strong>Hypothesis Generator</strong> (ranked hypotheses + concrete validation experiments).
        Validation uses <strong>public datasets only</strong> to avoid IP/data-use conflicts and to ensure reproducibility.
      </p>

      <div class="meta">
        Outputs: Versioned configs · Reproducible reports (HTML/PDF) · Figures · Methods · PubMed-linked evidence.
      </div>
    </section>

    <!-- WORKFLOW FIGURE -->
    <section class="section">
      <div class="card">
        <div class="kicker">Phase I Workflow Figure</div>

        <svg viewBox="0 0 1120 340" width="100%" height="auto" role="img" aria-label="PromptGenix Phase I workflow from inputs to pipelines, LLM interpretation, hypothesis generator, and reports"
             style="display:block;border-radius:14px;background:rgba(2,6,23,0.35);border:1px solid rgba(55,65,81,0.75);">
          <defs>
            <linearGradient id="g1" x1="0" y1="0" x2="1" y2="1">
              <stop offset="0%" stop-color="#22d3ee" stop-opacity="0.9"/>
              <stop offset="55%" stop-color="#6366f1" stop-opacity="0.9"/>
              <stop offset="100%" stop-color="#22c55e" stop-opacity="0.9"/>
            </linearGradient>

            <filter id="softGlow" x="-40%" y="-40%" width="180%" height="180%">
              <feGaussianBlur stdDeviation="8" result="blur"/>
              <feColorMatrix in="blur" type="matrix"
                values="1 0 0 0 0
                        0 1 0 0 0
                        0 0 1 0 0
                        0 0 0 0.55 0" result="glow"/>
              <feMerge>
                <feMergeNode in="glow"/>
                <feMergeNode in="SourceGraphic"/>
              </feMerge>
            </filter>

            <marker id="arrow" markerWidth="10" markerHeight="10" refX="9" refY="3" orient="auto">
              <path d="M0,0 L10,3 L0,6 Z" fill="#94a3b8" />
            </marker>

            <style>
              .bx { fill: rgba(15,23,42,0.92); stroke: rgba(148,163,184,0.55); stroke-width: 1.2; rx: 18; ry: 18; }
              .ttl { font: 700 16px -apple-system,BlinkMacSystemFont,Segoe UI,sans-serif; fill: #f9fafb; }
              .sub { font: 500 12.5px -apple-system,BlinkMacSystemFont,Segoe UI,sans-serif; fill: #d1d5db; }
              .tag { font: 600 11px -apple-system,BlinkMacSystemFont,Segoe UI,sans-serif; fill: #c7d2fe; }
              .line { stroke: rgba(148,163,184,0.75); stroke-width: 2; fill: none; marker-end: url(#arrow); }
              .badge { fill: rgba(15,23,42,0.9); stroke: rgba(129,140,248,0.55); stroke-width: 1; rx: 999; ry: 999; }
            </style>
          </defs>

          <rect x="22" y="18" width="1076" height="8" rx="8" fill="url(#g1)" filter="url(#softGlow)"/>

          <rect class="bx" x="40" y="60" width="240" height="210"/>
          <text class="ttl" x="64" y="92">Inputs</text>
          <text class="sub" x="64" y="118">• FASTQ / FCS</text>
          <text class="sub" x="64" y="140">• Public accession IDs</text>
          <text class="sub" x="64" y="162">• Minimal metadata</text>
          <rect class="badge" x="64" y="190" width="192" height="26"/>
          <text class="tag" x="80" y="208">Public-data Phase I</text>

          <rect class="bx" x="320" y="60" width="300" height="210"/>
          <text class="ttl" x="344" y="92">Automated Pipelines</text>
          <text class="sub" x="344" y="118">RNA-Seq: QC → align/quant → DEG → GSEA/GSVA</text>
          <text class="sub" x="344" y="142">Flow: QC → transforms → batch norm → summaries</text>
          <text class="sub" x="344" y="166">Versioned configs + reproducible outputs</text>

          <rect class="bx" x="660" y="60" width="260" height="210"/>
          <text class="ttl" x="684" y="92">Evidence-aware LLM</text>
          <text class="sub" x="684" y="118">• Interprets results</text>
          <text class="sub" x="684" y="140">• PubMed-linked evidence</text>
          <text class="sub" x="684" y="162">• Structured summaries</text>

          <rect x="684" y="182" width="212" height="64" rx="14" ry="14"
                fill="rgba(15,23,42,0.9)" stroke="rgba(34,197,94,0.55)" stroke-width="1.2"/>
          <text class="ttl" x="700" y="210" style="font-size:14px;">Hypothesis Generator</text>
          <text class="sub" x="700" y="232">Ranked hypotheses + experiments</text>

          <rect class="bx" x="960" y="60" width="120" height="210"/>
          <text class="ttl" x="976" y="92">Outputs</text>
          <text class="sub" x="976" y="118">HTML/PDF</text>
          <text class="sub" x="976" y="140">Figures</text>
          <text class="sub" x="976" y="162">Methods</text>
          <text class="sub" x="976" y="184">Citations</text>

          <path class="line" d="M280 165 C300 165, 300 165, 320 165"/>
          <path class="line" d="M620 165 C640 165, 640 165, 660 165"/>
          <path class="line" d="M920 165 C940 165, 940 165, 960 165"/>

          <rect x="40" y="288" width="1040" height="36" rx="14" fill="rgba(15,23,42,0.78)" stroke="rgba(55,65,81,0.85)"/>
          <text class="sub" x="64" y="311">
            Phase I KPIs: ≥70% faster turnaround · ≥90% reproducibility · ≥80% hypothesis usefulness (pilot rubric)
          </text>
        </svg>

        <div class="mini">Vector SVG: prints cleanly to PDF and scales well on mobile (no asset upload needed).</div>
      </div>
    </section>

    <!-- APPROACH DETAILS -->
    <section class="section">
      <div class="grid">
        <div class="card">
          <div class="kicker">A. Pipeline hardening</div>
          <h2>Make RNA-Seq and flow cytometry workflows robust, repeatable, and reviewer-traceable.</h2>
          <ul>
            <li><strong>RNA-Seq:</strong> QC → alignment/quantification → differential expression → GSEA/GSVA, with versioned configs and deterministic outputs.</li>
            <li><strong>Flow cytometry:</strong> preprocessing/QC, transforms, batch normalization, and summary exports (for downstream statistics + reporting).</li>
            <li><strong>Reproducibility:</strong> run manifests, environment/version stamping, and standardized report structure for easy audit.</li>
          </ul>
          <div class="callout">
            <strong>Phase I constraint:</strong> public datasets only (GEO/SRA/FlowRepository), enabling conflict-free validation.
          </div>
        </div>

        <div class="card">
          <div class="kicker">B. Literature-aware hypothesis generator</div>
          <h2>Generate ranked hypotheses and concrete follow-up experiments with PubMed traceability.</h2>
          <ul>
            <li><strong>Evidence linkage:</strong> connect literature mechanisms to observed signals (DEG, pathways, immune subsets).</li>
            <li><strong>Hypothesis ranking:</strong> score by strength/consistency of evidence + coherence with the dataset.</li>
            <li><strong>Experiment suggestions:</strong> propose actionable validation steps (panel refinements, contrasts, perturbations) with citations.</li>
          </ul>
          <div class="callout">
            <strong>Deliverable:</strong> a structured “Hypothesis Table” in the report with citations and proposed tests.
          </div>
        </div>
      </div>
    </section>

    <!-- VALIDATION PLAN TABLE -->
    <section class="section" id="validation">
      <div class="card">
        <div class="kicker">C. Phase I Validation Plan</div>
        <h2>Public-data validation with measurable KPIs and reviewer-ready outputs.</h2>
        <p>
          Phase I evaluation focuses on pipeline stability, reproducibility, speed, and user-rated usefulness of
          AI-generated hypotheses. Datasets are selected to represent typical NIH lab workflows and common failure modes
          (batch effects, heterogeneous cohorts, noisy markers).
        </p>

        <div class="table-wrap" style="margin-top:12px;">
          <table>
            <thead>
              <tr>
                <th>Module</th>
                <th>Public dataset type (examples)</th>
                <th>Validation outputs</th>
                <th>Success metrics (examples)</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td>
                  <div class="pill">RNA-Seq</div>
                  <div class="pill">DEG</div>
                  <div class="pill">GSEA/GSVA</div>
                </td>
                <td>
                  GEO/SRA bulk RNA-Seq study with case/control contrasts and batch variation.
                  <div class="mini">Goal: stable alignment/quant + consistent DEG + pathway results.</div>
                </td>
                <td>
                  HTML/PDF report, QC figures, DEG tables, pathway enrichment, methods.
                </td>
                <td>
                  ≥90% reproducibility across reruns; ≥70% reduction in turnaround time vs manual baseline.
                </td>
              </tr>

              <tr>
                <td>
                  <div class="pill">Flow cytometry</div>
                  <div class="pill">Batch norm</div>
                  <div class="pill">Summaries</div>
                </td>
                <td>
                  FlowRepository dataset with multi-batch samples and common immunophenotyping panels.
                  <div class="mini">Goal: robust preprocessing + consistent summary outputs.</div>
                </td>
                <td>
                  Standardized preprocessing outputs, summary tables/figures, exportable report sections.
                </td>
                <td>
                  Reduced batch-driven variance (pre/post metrics); stable outputs across reruns.
                </td>
              </tr>

              <tr>
                <td>
                  <div class="pill">LLM layer</div>
                  <div class="pill">Interpretation</div>
                </td>
                <td>
                  Any of the above (paired with results artifacts).
                  <div class="mini">Goal: clear narrative + traceable claims to evidence.</div>
                </td>
                <td>
                  Structured summary, evidence-linked narrative, citations, limitations.
                </td>
                <td>
                  Pilot rubric: ≥80% “useful/very useful” ratings on interpretability.
                </td>
              </tr>

              <tr>
                <td>
                  <div class="pill">Hypothesis Generator</div>
                  <div class="pill">PubMed-aware</div>
                </td>
                <td>
                  Public datasets with known mechanisms or established literature context.
                  <div class="mini">Goal: hypotheses that are plausible, testable, and cited.</div>
                </td>
                <td>
                  Ranked hypothesis list + proposed validation experiments + citations.
                </td>
                <td>
                  Pilot rubric: ≥80% hypotheses rated “plausible & actionable”; citation traceability maintained.
                </td>
              </tr>
            </tbody>
          </table>
        </div>

        <div class="callout" style="margin-top:12px;">
          <strong>Phase I deliverables alignment:</strong> D1 (harden pipelines) · D2 (hypothesis generator with citations) ·
          D3 (reviewer-ready reports within &lt;24 hours).
        </div>
      </div>
    </section>

    <!-- RISKS & MITIGATIONS -->
    <section class="section" id="risks">
      <div class="card">
        <div class="kicker">Risks & Mitigations</div>
        <h2>Phase I technical risks are known and manageable with clear mitigations.</h2>
        <p>
          Phase I focuses on hardening, traceability, and public-data validation. The table below summarizes
          anticipated risks and concrete mitigations that keep deliverables on schedule.
        </p>

        <div class="table-wrap" style="margin-top:12px;">
          <table>
            <thead>
              <tr>
                <th>Risk</th>
                <th>Why it matters</th>
                <th>Mitigation (Phase I)</th>
                <th>Go / No-Go criteria</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td><strong>Public dataset heterogeneity</strong><br/><span class="mini">formats, metadata gaps</span></td>
                <td>Inconsistent inputs can break automation and reduce reproducibility.</td>
                <td>
                  Standard ingestion templates; robust parsers; minimum metadata requirements;
                  fail-fast checks with actionable error messages.
                </td>
                <td>
                  ≥3 datasets processed end-to-end without manual code edits; documented input schema.
                </td>
              </tr>

              <tr>
                <td><strong>Batch effects confound signals</strong><br/><span class="mini">flow and RNA-Seq</span></td>
                <td>False positives/negatives degrade trust and usability.</td>
                <td>
                  Batch-aware normalization options; pre/post batch diagnostics in the report;
                  transparent methods and limitations.
                </td>
                <td>
                  Demonstrable reduction in batch-driven variance; stable results across reruns.
                </td>
              </tr>

              <tr>
                <td><strong>LLM hallucination / unverifiable claims</strong><br/><span class="mini">scientific narrative risk</span></td>
                <td>Untraceable statements are unacceptable for reviewers and PIs.</td>
                <td>
                  Structured templates; citations required for mechanistic claims; “evidence level” labels;
                  uncertainty + “what would falsify this” prompts.
                </td>
                <td>
                  All hypotheses include citations or are explicitly marked speculative with rationale.
                </td>
              </tr>

              <tr>
                <td><strong>Hypotheses not actionable</strong><br/><span class="mini">too generic / not testable</span></td>
                <td>Value depends on producing experiments a lab can realistically run.</td>
                <td>
                  Enforce testability fields (assay/panel/contrast); rank by actionability;
                  complexity tags; pilot feedback loop.
                </td>
                <td>
                  ≥80% pilot-rated “plausible & actionable” on a structured rubric.
                </td>
              </tr>

              <tr>
                <td><strong>Compute/time constraints</strong><br/><span class="mini">local vs cloud</span></td>
                <td>Long runtimes reduce adoption and Phase I throughput.</td>
                <td>
                  Modular execution; caching intermediates; local or AWS VPC execution;
                  prioritize “good defaults” over exhaustive search in Phase I.
                </td>
                <td>
                  Reviewer-ready report produced in &lt;24 hours from raw inputs on target hardware profile.
                </td>
              </tr>
            </tbody>
          </table>
        </div>

        <div class="callout" style="margin-top:12px;">
          <strong>Phase I readiness:</strong> Mitigations are implemented as product features (templates, constraints,
          traceability, reporting), not manual reviewer-dependent steps.
        </div>
      </div>
    </section>

    <!-- CLOSE -->
    <section class="section">
      <div class="card">
        <div class="kicker">Next</div>
        <h2>Use this page as your Phase I “Approach” narrative.</h2>
        <ul>
          <li>Replace dataset “examples” later with specific GEO/SRA/FlowRepository accession IDs.</li>
          <li>Export this page to PDF for reviewer-friendly appendices or Program Officer discussions.</li>
          <li>Next step: create a one-page “Commercialization” summary and a Letter-of-Support outreach email template.</li>
        </ul>

        <div style="margin-top:12px;display:flex;gap:10px;flex-wrap:wrap;">
          <a class="btn btn-outline" href="aims.html">Back to Specific Aims</a>
          <a class="btn btn-primary" href="mailto:dohoon.kim1@icloud.com?subject=PromptGenix%20SBIR%20Pilot%20/LOS">
            Request pilot / Letter of Support
          </a>
        </div>
      </div>
    </section>

  </main>

  <footer>
    PromptGenix &middot; Research Strategy – Approach (Phase I) &middot;
    Contact: <a href="mailto:dohoon.kim1@icloud.com">dohoon.kim1@icloud.com</a>
  </footer>
</div>
</body>
</html>
